Altimmune fell 16.6% after earnings, despite management’s positive framing. The transcript offers no new financial or clinical setback; the likely source of disappointment is the long wait for the pivotal PERFORMA readout, expected in 2029, with enrollment still ramping and ex-U.S. sites yet to activate.
- PERFORMA Phase 3 is screening and dosing patients; the majority of planned U.S. sites are active, while ex-U.S. sites are expected to activate over the coming months.
- The company anticipates PERFORMA’s 52-week data readout in 2029, leaving a lengthy timeline to a key MASH milestone.
- Management said new 48-week IMPACT data highlighted antifibrotic activity; the study was published in *The Lancet* this week.
- RECLAIM Phase 2 data in alcohol use disorder were presented as a late-breaking oral presentation; an FDA end-of-Phase 2 meeting is scheduled for next month.
- Management cited estimates that 55%–94% of alcohol-related liver disease patients also meet criteria for alcohol use disorder, supporting its rationale for developing pemvidutide across both indications.
Community Discussion